<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ocular myasthenia gravis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ocular myasthenia gravis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Ocular myasthenia gravis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Victoria S Pelak, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Dianna Quan, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan Trobe, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeremy M Shefner, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Janet L Wilterdink, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 23, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Myasthenia gravis (MG) is an autoimmune disorder characterized by weakness and fatigability of skeletal muscles. Muscle weakness due to dysfunction of the neuromuscular junction (myasthenia) is usually an acquired disorder, and the vast majority of patients who develop generalized myasthenia in adolescence or adulthood have autoantibodies that play a pathogenetically important role. Such antibody-mediated disease is referred to as MG.</p><p>When the clinical manifestations of MG are isolated to the levator palpebrae superioris, orbicularis oculi, and extraocular muscles affecting eye movement, it is referred to as ocular MG (OMG). Over one-half of all patients with MG initially present with isolated ptosis, diplopia, or both, and no signs or symptoms of weakness elsewhere [<a href="#rid1">1-4</a>]. Approximately 15 percent of all patients with MG have isolated OMG as the only manifestation of their disease. Although the disease pathology at the neuromuscular junction is not known to be distinct from generalized MG (GMG), there are several important and unique differences between OMG and GMG with regard to diagnosis and treatment.</p><p>This topic will discuss OMG. Other aspects of MG are discussed separately. (See  <a class="medical medical_review" href="/d/html/5153.html" rel="external">"Pathogenesis of myasthenia gravis"</a> and  <a class="medical medical_review" href="/d/html/5170.html" rel="external">"Clinical manifestations of myasthenia gravis"</a> and  <a class="medical medical_review" href="/d/html/5168.html" rel="external">"Differential diagnosis of myasthenia gravis"</a> and  <a class="medical medical_review" href="/d/html/5130.html" rel="external">"Diagnosis of myasthenia gravis"</a> and  <a class="medical medical_review" href="/d/html/5157.html" rel="external">"Overview of the treatment of myasthenia gravis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>The pathophysiology of OMG is believed to be identical to that for generalized MG (GMG). (See  <a class="medical medical_review" href="/d/html/5153.html" rel="external">"Pathogenesis of myasthenia gravis"</a>.)</p><p>It is uncertain why ocular muscles are frequently involved in myasthenia and why the disease stays localized to the extraocular muscles in 15 percent of cases. It has been proposed that subtle alterations in the function of extraocular muscles are more likely to produce symptoms there than in limb muscles, and that the levator palpebrae superioris, under constant activation during eye opening, may be especially susceptible to fatigue. Other factors may contribute to this phenomenon [<a href="#rid5">5-7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with OMG are more likely to be seronegative for acetylcholine receptor antibodies (AChR-Ab) than patients with GMG.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extraocular muscles (but not the levator palpebrae superioris) are unique in their expression of fetal acetylcholine receptors at the neuromuscular junction; however, there is no evidence for specific immunologic targeting of this receptor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The junctional folds of muscle endplates are sparse in the extraocular and levator muscles, perhaps producing a lower safety factor for neuromuscular transmission.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complement regulatory genes are expressed differently in extraocular muscles, perhaps reducing protective mechanisms to complement-mediated tissue injury.</p><p></p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>OMG is characterized by ptosis and ophthalmoparesis (weakness of the muscles controlling eye movement) and extraocular muscle weakness. Some patients also have mild orbicularis oculi weakness and thus have difficulty closing the eye. This triad (ptosis, ophthalmoparesis, and orbicularis oculi weakness) should prompt an evaluation for MG.</p><p>As with generalized MG (GMG), signs and symptoms of OMG are characterized by fluctuating, fatigable weakness. Most patients note symptoms that worsen as the day progresses or with tasks such as driving. Patients may report that they have mild or no symptoms upon awakening. The examination may elicit signs of fatigable levator and extraocular muscle weakness.</p><p class="headingAnchor" id="H4"><span class="h2">Ptosis</span><span class="headingEndMark"> — </span>Ptosis is often unilateral or asymmetric on presentation. A historical pattern of ptosis alternating from one side to the other is nearly always a sign of OMG. Old photos may help to determine if ptosis is new or longstanding. Measurements of the eyelid position and levator palpebrae superioris function using standard methods help to identify and quantify weakness as well as fluctuations associated with fatigue. (See  <a class="medical medical_review" href="/d/html/5243.html" rel="external">"Overview of ptosis"</a>.)</p><p class="headingAnchor" id="H5"><span class="h3">Examination for eyelid fatigue</span><span class="headingEndMark"> — </span>Fluctuation present during the examination suggests fatigability of the levator muscle. Fatigability can also be elicited with the following maneuvers:</p><p class="bulletIndent1"><span class="glyph">●</span>Sustained upgaze. The patient is instructed to maintain upgaze for one to two minutes. Enhancement of ptosis during prolonged upgaze or upon return to primary gaze suggests fatigability.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Shifting from downgaze to primary gaze. The patient is asked to sustain downgaze briefly and then make a fast conjugate eye movement (saccade) to primary gaze. An affected eyelid will quickly rise and then fall (by as little as 1 mm or more), such that the lid appears to twitch (Cogan lid twitch sign) [<a href="#rid8">8</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rest test. Improvement in baseline ptosis after a two- to five-minute period of restful lid closure suggests fatigability.</p><p></p><p>While each of these signs suggests fatigable levator function, none are specific for OMG. </p><p class="headingAnchor" id="H1854062477"><span class="h3">Ice pack test</span><span class="headingEndMark"> — </span>In patients with myasthenia, ptosis typically improves after the application of ice to the upper lid. The sensitivity of this test is approximately 80 percent in those with prominent ptosis [<a href="#rid9">9,10</a>]. The predictive value of this test has not been established. The test is not diagnostic but can help to raise suspicion for myasthenia.</p><p>To perform the test, a bag is filled with ice and placed on the closed eyelid for one minute. The ice is then removed and the extent of ptosis (and ocular misalignment) is assessed immediately; the duration of improvement is short (less than one minute). The change in muscle strength is based on the physiologic principle of improved neuromuscular transmission at lower muscle temperature.</p><p>The utility of the ice pack test to assess ophthalmoparesis has not been investigated in a controlled manner; some authors have noted detectable changes in ocular alignment [<a href="#rid11">11</a>]. </p><p class="headingAnchor" id="H6"><span class="h2">Diplopia</span><span class="headingEndMark"> — </span>Binocular diplopia (diplopia that is present only with both eyes open) is a prominent feature of OMG when ophthalmoparesis (weakness of the eye muscles controlling eye movement) is present. At presentation, OMG may involve individual or multiple extraocular motor muscles in one or both eyes. For patients with medial or lateral rectus muscle involvement, diplopia will be binocular and horizontal. If the superior or inferior recti or the oblique muscles are involved, there will be a vertical or diagonal component to the diplopia.</p><p>Any pattern of ocular misalignment may be observed in OMG, including those that are caused by isolated oculomotor cranial nerve palsies and central nervous system brainstem pathway lesions such as internuclear ophthalmoplegia.</p><p>The cardinal positions of gaze should be tested and observed for paresis. (See  <a class="medical medical_review" href="/d/html/5238.html" rel="external">"Overview of diplopia", section on 'Examination'</a>.)</p><p>As with ptosis, OMG can result in fatigable ocular motility. Fluctuation in either the degree of diplopia or the direction of gaze that elicits the diplopia suggests fatigable ophthalmoparesis. Prolonged or sustained gaze in the direction of action of an involved muscle may result in fatigue of the muscle with increasing paresis [<a href="#rid12">12</a>]. </p><p>Similarly, repeated measurements using a Maddox rod or red glass during or after sustained gaze may reveal increasing degrees of strabismus (ocular misalignment). For the red glass test, a translucent red glass is placed over one eye of the patient while the patient is looking at a light. It is best to use a light source with a focused beam. The patient with ophthalmoparesis will see one red light and one white light, and the relationship of the two lights allows the examiner to determine the type of ocular misalignment that is causing the double vision. For example, when the red glass is placed over the right eye and the patient reports that the red light is to the right of the white light, then the eyes are directed toward each other, as noted with lateral rectus weakness of either eye. </p><p>An alternative to the red glass is a Maddox rod, in which the red glass is replaced by parallel translucent cylinder lines. The Maddox rod is more commonly used than the red glass. With the same technique as described in the red glass test, a patient places the Maddox rod over one eye and looks at a light source. The patient will see a red line with the eye with the Maddox rod over it and a white light with the fellow eye [<a href="#rid13">13</a>]. The findings help identify the misalignment but cannot identify whether both eyes or one eye is weak. However, after testing in multiple positions of gaze (ie, up, right, left, down), the examiner can pinpoint the weak extraocular muscles by noting the pattern of misalignment. (See  <a class="medical medical_review" href="/d/html/5238.html" rel="external">"Overview of diplopia", section on 'Examination'</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Other findings</span><span class="headingEndMark"> — </span>Difficulty closing the eye fully (lagophthalmus) is rare in OMG. However, some weakness of the orbicularis oculi is often demonstrable when the examiner attempts to open the eyes against forced eyelid closure, nearly impossible in an unaffected patient. The "peek-a-boo" sign of lagophthalmus after prolonged forced eyelid closure suggests fatigue in this muscle.</p><p>When the more ptotic eyelid is lifted above the iris by the examiner, the contralateral eyelid drops ("curtaining"). This phenomenon results because of the law of equal innervation to both levator palpebrae superioris muscles (Hering's law) [<a href="#rid14">14</a>]. Eyelid curtaining has also been described in cases of third nerve palsies and in cases of narrowed palpebral fissures due to peripheral facial palsies [<a href="#rid14">14,15</a>].</p><p>Anisocoria and failure of pupil constriction to light are not<strong> </strong>observed in OMG. Subclinical pupil sphincter fatigue with repeated light stimulation as well as accommodative fatigue have been reported; however, we do not routinely evaluate for these [<a href="#rid16">16,17</a>].</p><p>The use of <a class="drug drug_general" data-topicid="9403" href="/d/drug information/9403.html" rel="external">edrophonium</a> (Tensilon) in the evaluation of myasthenia has fallen out of use, and the drug is no longer available in the United States and many other countries [<a href="#rid18">18</a>]. The sensitivity of the Tensilon test for OMG was 85 to 95 percent, similar to that for GMG, but it was associated with false-positive results [<a href="#rid19">19-21</a>]. (See  <a class="medical medical_review" href="/d/html/5130.html" rel="external">"Diagnosis of myasthenia gravis", section on 'Pharmacologic testing'</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of the clinical manifestations of OMG depends on the symptom cluster:</p><p class="bulletIndent1"><span class="glyph">●</span>Isolated ptosis</p><p class="bulletIndent1"><span class="glyph">●</span>Isolated ophthalmoparesis</p><p class="bulletIndent1"><span class="glyph">●</span>Ptosis and ophthalmoparesis</p><p class="bulletIndent1"><span class="glyph">●</span>Ptosis, ophthalmoparesis, and other signs or symptoms of bulbar weakness</p><p></p><p>The differential diagnosis of isolated ptosis and ophthalmoparesis is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/5243.html" rel="external">"Overview of ptosis"</a> and  <a class="medical medical_review" href="/d/html/5238.html" rel="external">"Overview of diplopia"</a>.)</p><p>Conditions that cause bilateral impairment of both eyelid and extraocular muscle function are most likely to be considered in the differential diagnosis of OMG.</p><p class="headingAnchor" id="H9"><span class="h2">Thyroid ophthalmopathy</span><span class="headingEndMark"> — </span>Graves' disease produces restricted eye movements due to a constrictive ophthalmopathy. It can usually be differentiated from MG by the lack of ptosis and the presence of proptosis, lid retraction, lid lag, and periorbital edema. However, thyroid disease can coexist with MG. (See  <a class="medical medical_review" href="/d/html/7825.html" rel="external">"Clinical features and diagnosis of thyroid eye disease"</a>.)</p><p>Restricted eye movement in Graves' ophthalmopathy can be confirmed by forced duction testing, which involves grasping the extraocular muscle insertion with a forceps or placing a suction cup on the eye and rotating the eye manually in the direction of the reduced movement. If the reduced excursion cannot be overcome with these maneuvers, the diagnosis is a shortened muscle rather than weakness. </p><p>In addition, the enlarged extraocular muscles of Graves' disease can usually be seen on computed tomography (CT) images of the orbits. </p><p>Because MG and Graves' disease can be comorbid, we recommend thyroid function studies before treatment of OMG is instituted, even when the diagnosis of OMG is clear.</p><p class="headingAnchor" id="H10"><span class="h2">Chronic progressive external ophthalmoplegia</span><span class="headingEndMark"> — </span>Chronic progressive external ophthalmoplegia (CPEO) and Kearns-Sayre syndrome (KSS) are mitochondrial disorders that produce progressive and generally symmetric ophthalmoparesis and ptosis. In KSS and CPEO, saccades are generally slow in all directions, whereas in OMG, saccades are of normal velocity even if they are of limited amplitude.</p><p>CPEO generally remains isolated to the extraocular muscles, but some CPEO syndromes and KSS involve other findings, including generalized muscle weakness, cerebellar ataxia, and reduced vision from retinal degeneration, abnormalities not found in OMG [<a href="#rid22">22</a>]. Most patients with KSS present with ptosis months to years before the onset of ophthalmoparesis. Because of the symmetric nature of the ophthalmoparesis, patients with KSS and CPEO typically do not complain of diplopia except at reading distance, where reduced convergence creates ocular misalignment. (See  <a class="medical medical_review" href="/d/html/6271.html" rel="external">"Myopathies affecting the extraocular muscles in children", section on 'Kearns-Sayre syndrome'</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Muscular dystrophy</span><span class="headingEndMark"> — </span>Myotonic dystrophy and oculopharyngeal dystrophy may produce ptosis and ophthalmoparesis.</p><p>Myotonic dystrophy is an autosomal dominant disorder characterized by variable ptosis and weakness of the face, jaw, and neck as well as weakness of the extremities. Associated abnormalities include cataracts, cardiac conduction defects, characteristic facies (long face with atrophy of temporalis and masseter), frontal balding, and variable intellectual impairment. Patients may also develop dysphagia and ophthalmoparesis in some cases. (See  <a class="medical medical_review" href="/d/html/5147.html" rel="external">"Myotonic dystrophy: Etiology, clinical features, and diagnosis"</a>.)</p><p>Oculopharyngeal dystrophy is characterized by slowly progressive ptosis and dysphagia with onset in the fourth or fifth decade of life. Weakness of the proximal muscles is commonly present upon initial presentation, but ophthalmoparesis typically develops after the onset of ptosis and dysphagia. (See  <a class="medical medical_review" href="/d/html/6180.html" rel="external">"Oculopharyngeal, distal, and congenital muscular dystrophies", section on 'Oculopharyngeal muscular dystrophy'</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Brainstem and motor cranial nerve pathologies</span><span class="headingEndMark"> — </span>Structural disease of the brainstem can cause manifestations that resemble OMG. As examples, parasellar tumors and aneurysms can impair function of the third, fourth, and sixth cranial nerves [<a href="#rid23">23-25</a>]. The presence of trigeminal dysfunction and/or pupillary abnormalities is inconsistent with OMG and may point to a structural lesion. Brain magnetic resonance imaging (MRI) to exclude these disorders is warranted in unconfirmed cases of OMG.</p><p>Multiple motor cranial neuropathies, such as those produced by carcinomatous or lymphomatous meningitis, may also produce eye movement abnormalities that may be confused with MG. If the diagnosis of MG is not firmly established in cases of possible multiple cranial nerve abnormalities, examination of the cerebrospinal fluid for abnormal cells and cytology is usually necessary.</p><p>In one case series of 979 patients with multiple cranial nerve palsies (not necessarily including or isolated to the oculomotor cranial nerves), tumor was the most prevalent cause (30 percent) [<a href="#rid26">26</a>]. Other causes included vascular disease, trauma, infection, Guillain-Barré syndrome, cavernous sinusitis, diabetes, and multiple sclerosis.</p><p class="headingAnchor" id="H13"><span class="h1">EVALUATION AND DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of OMG should be suspected in a patient with typical history and examination findings and a positive result on ice test. Further confirmation should be obtained by a positive acetylcholine receptor antibody (AChR-Ab) titer. If this is negative (as it will be in approximately half of patients with OMG), then electromyography (EMG) with repetitive nerve stimulation (RNS) or single-fiber EMG (SFEMG) should be performed. If the titer is positive, then electrophysiologic testing is generally unnecessary. The sensitivity and specificity of tests are different for generalized MG (GMG) versus OMG  (<a class="graphic graphic_table graphicRef77349" href="/d/graphic/77349.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H16"><span class="h2">Serum antibody studies</span><span class="headingEndMark"> — </span>While more than 85 percent of patients with GMG have serum AChR-Ab [<a href="#rid7">7,27-30</a>], the sensitivity of AChR-Ab testing in OMG may be as low as 45 to 60 percent [<a href="#rid27">27,31,32</a>]. However, this is the most specific test for MG; no false positives have been reported (100 percent specificity). (See  <a class="medical medical_review" href="/d/html/5130.html" rel="external">"Diagnosis of myasthenia gravis", section on 'Acetylcholine receptor antibodies'</a>.)</p><p>Some patients with GMG who are seronegative for AChR-Ab have antibodies against the muscle-specific tyrosine kinase (MuSK) [<a href="#rid33">33-35</a>]. Once thought to be unassociated with OMG, MuSK antibodies have been detected in patients with OMG in a few case reports [<a href="#rid36">36-38</a>]. (See  <a class="medical medical_review" href="/d/html/5130.html" rel="external">"Diagnosis of myasthenia gravis", section on 'MuSK antibodies'</a>.)</p><p>A number of reports have linked low-density lipoprotein receptor-related protein 4 (LRP4) antibodies with GMG [<a href="#rid39">39</a>]. In three reported cases of OMG, patients who were found to be seronegative for both AChR-Ab and MuSK were found to have positive LRP4 antibodies [<a href="#rid40">40</a>]. Other antibodies with a potential role in the pathogenesis and diagnosis of GMG are discussed separately. (See  <a class="medical medical_review" href="/d/html/5130.html" rel="external">"Diagnosis of myasthenia gravis", section on 'LRP4 antibodies'</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Electrophysiology</span><span class="headingEndMark"> — </span>Electrodiagnostic studies are an important supplement to the immunologic studies and may also provide confirmation of the diagnosis of myasthenia. These tests may not be necessary if serum antibody tests are diagnostic.</p><p class="headingAnchor" id="H18"><span class="h3">Repetitive nerve stimulation</span><span class="headingEndMark"> — </span>Repetitive nerve stimulation (RNS) studies demonstrate decrement in the amplitude of the compound muscle action potential after repetitive stimulation of the motor nerve to that muscle [<a href="#rid41">41</a>] (see  <a class="medical medical_review" href="/d/html/5130.html" rel="external">"Diagnosis of myasthenia gravis", section on 'Nerve conduction testing with repetitive nerve stimulation'</a>). The orbicularis oculi may be studied in patients with OMG.</p><p>Among patients with GMG, the sensitivity of RNS is greater than 70 percent [<a href="#rid42">42</a>]. By contrast, among patients with OMG, the sensitivity was as low as 15 percent in some series, and only somewhat higher, 33 to 45 percent, in series where stimulation at multiple sites was performed [<a href="#rid43">43,44</a>]. The specificity is 89 percent; both false negatives and false positives do occur [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H19"><span class="h3">Single-fiber EMG</span><span class="headingEndMark"> — </span>SFEMG identifies abnormal neuromuscular transmission by measuring temporal variability in the firing of adjacent motor nerve fibers from a single motor unit, a phenomenon called "jitter." SFEMG is more sensitive than RNS and may identify electrophysiologic abnormalities in clinically strong muscles. (See  <a class="medical medical_review" href="/d/html/5130.html" rel="external">"Diagnosis of myasthenia gravis", section on 'Single-fiber electromyography'</a>.)</p><p>Depending on which and how many muscles are examined, the sensitivity of SFEMG for OMG is between 63 and 100 percent [<a href="#rid45">45-47</a>]. Evaluation of the orbicularis oculi and frontalis muscles increases the sensitivity in patients with OMG [<a href="#rid47">47,48</a>]. However, this testing is available only at specialized centers with neuromuscular expertise.</p><p>Abnormal jitter is not specific for myasthenia. However, while patients with MG generally have an otherwise normal standard EMG examination, other neuromuscular diseases that increase jitter do not. An exception may be in differentiating patients suspected of OMG from those with chronic progressive external ophthalmoplegia (CPEO). CPEO is often, but not always, associated with a myopathic pattern on EMG, and SFEMG does not clearly help distinguish these two entities. Two reports give conflicting data: in the presence of a normal needle EMG examination, one showed abnormal SFEMG in CPEO [<a href="#rid49">49</a>], while the other did not [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H4248439296"><span class="h2">Additional testing</span><span class="headingEndMark"> — </span>If the diagnosis remains unclear after serum antibody testing and/or EMG, brain magnetic resonance imaging (MRI) and lumbar puncture (LP) with spinal fluid examination may be needed to exclude treatable inflammatory or structural disease of the brainstem or cranial nerve roots [<a href="#rid23">23-25</a>]. (See <a class="local">'Differential diagnosis'</a> above.)</p><p>Patients with suspected OMG should also have a chest computed tomography (CT) scan to rule out thymoma and thyroid function tests to rule out associated thyroid dysfunction.</p><p class="headingAnchor" id="H21"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Of patients presenting with OMG, two-thirds will go on to develop signs and symptoms of extremity weakness and other bulbar muscle weakness, while one-third will continue to have pure OMG [<a href="#rid2">2,3</a>]. Most (78 percent) of those who will develop generalized MG (GMG) will do so within the first year, and 94 percent will do so within three years.</p><p>Neither age nor sex has been consistently shown to alter the course of disease. A normal single-fiber electromyography (SFEMG) study may be helpful in stratifying risk of generalization. In one study of 37 patients with OMG followed for two years, 82 percent of those with normal SFEMG in the extensor digitorum communis persisted with isolated OMG, whereas 58 percent of those with an abnormal study developed GMG [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H22"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Treatment considerations in the management of OMG include symptomatic and immunomodulatory treatment of myasthenia, thymectomy, and corrective treatments of ptosis and strabismus.</p><p>In patients with MG, certain drugs prescribed for coexisting medical conditions may exacerbate muscle weakness. A few medications such as fluoroquinolones and telithromycin carry US Food and Drug Administration (FDA) "black box warnings" for patients with MG  (<a class="graphic graphic_table graphicRef100362" href="/d/graphic/100362.html" rel="external">table 2</a>). Patients should be advised to discuss all new medications with their physicians.</p><p class="headingAnchor" id="H23"><span class="h2">Symptomatic management of ptosis and diplopia</span><span class="headingEndMark"> — </span>Assistive devices to keep the ptotic lid(s) elevated can be used pending a response to acetylcholinesterase inhibitors or immunosuppressive therapy. Devices consist of a ptosis "crutch" or lid adhesive tapes, but these are problematic due to discomfort and corneal dryness, and crutches are difficult to find.</p><p>An eye patch, opaque contact lens, or occlusion of an eyeglass lens are simple ways to eliminate diplopia. A patch that is concave (to avoid injury to the cornea) can be worn over either eye; it is not necessary to alternate the patch between eyes in adults. Occlusion of an eyeglass lens with opaque tape works as an eye patch does. For cosmetic reasons, an opaque contact lens may be more acceptable than patching or an opaque eyeglass lens. These interventions also have the disadvantage of eliminating depth perception, which usually requires unoccluded vision in two eyes. Some patients require stereoscopic vision in their occupation. Other activities of daily living, such as driving and watching television, are also impaired with a loss of depth perception; however, many patients are willing to sacrifice depth perception in favor of eliminating diplopia.</p><p>Prism lenses offer another nonpharmacologic alternative for patients with diplopia. If the ophthalmoparesis is stable over several weeks or months, prism lenses may minimize diplopia. However, fatigability and significant variability of eye movements and ocular alignment will limit the benefit of prisms in patients with OMG until stabilization occurs. Press-on, flexible prism lenses are a less expensive and more adaptable alternative than ground-in prism lenses, and they can be removed if there is considerable fluctuation of the ophthalmoparesis. A disadvantage is that they can distort vision when the prism strength is high.</p><p class="headingAnchor" id="H24"><span class="h2">Anticholinesterase agents</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9838" href="/d/drug information/9838.html" rel="external">Pyridostigmine</a> (Mestinon) is the most commonly used anticholinesterase agent for symptomatic treatment of myasthenia. No randomized trials have studied the efficacy of anticholinesterase agents in OMG [<a href="#rid52">52</a>]. Unfortunately, in our clinical experience, pyridostigmine treatment alone rarely results in resolution of ocular symptoms, particularly diplopia. In one case series, pyridostigmine treatment alone produced resolution of primary gaze diplopia in only 6.9 percent [<a href="#rid53">53</a>]. It is best used for very mild cases of OMG or as adjunctive symptomatic treatment for moderate or severe OMG. The dosing regimen and side-effect profile for pyridostigmine are the same for patients with generalized MG (GMG) and OMG. (See  <a class="medical medical_review" href="/d/html/5157.html" rel="external">"Overview of the treatment of myasthenia gravis", section on 'Initial symptomatic therapy'</a>.)</p><p class="headingAnchor" id="H25"><span class="h2">Immunosuppressive agents</span><span class="headingEndMark"> — </span>Some clinicians prefer to reserve immunosuppressive treatment for patients with more severe disease than that manifested by pure OMG. However, in order to achieve resolution of ptosis or ophthalmoparesis, patients with OMG usually require immunosuppression. Many patients are not satisfied with eye patching, prism lenses, or nonpharmacologic therapy and prefer immunosuppression despite the known risks.</p><p>Retrospective data indicate that immunosuppressive treatment of OMG may decrease the likelihood of developing GMG [<a href="#rid52">52,54-56</a>]. It is not clear from these studies whether treatment actually reduces the incidence of GMG, delays its onset, or just masks its symptoms. Prospective studies are needed to confirm this finding [<a href="#rid52">52</a>].</p><p>Plasmapheresis and intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> are used for the short-term management of severe GMG and are used only in OMG when bilateral ptosis is debilitating. (See  <a class="medical medical_review" href="/d/html/5157.html" rel="external">"Overview of the treatment of myasthenia gravis", section on 'Plasma exchange and IVIG as rescue or bridge therapies'</a>.)</p><p class="headingAnchor" id="H26"><span class="h3">Prednisone</span><span class="headingEndMark"> — </span>The most commonly used immunosuppressive agent for the treatment of myasthenia is <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>. However, the use of corticosteroids in OMG is somewhat controversial [<a href="#rid57">57,58</a>]. In making a decision to use corticosteroids in OMG, clinicians and patients must balance the severity of their symptoms and the efficacy of nonpharmacologic measures (eg, ptosis tape to elevate the eyelid and patching to eliminate diplopia) with the difficulty in weaning prednisone in some patients and the side effects associated with corticosteroid therapy. Also, 10 percent of patients with OMG will have spontaneous remission without corticosteroids [<a href="#rid58">58</a>].</p><p>The efficacy of corticosteroids was demonstrated in a case series of 55 patients with OMG [<a href="#rid53">53</a>]. <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">Prednisone</a> produced symptom resolution at one month in approximately 70 percent that was sustained over a two-year follow-up period. Another observational study of 35 patients found that ocular symptoms were more likely to resolve with corticosteroids than with anticholinesterase treatment (70 versus 29 percent) [<a href="#rid59">59</a>].</p><p>In addition to symptomatic benefit, there are some studies that suggest that treatment with corticosteroids may reduce the progression to GMG [<a href="#rid54">54,55,60-62</a>]. As an example, one retrospective study found that among 56 patients with OMG assessed at two years after onset of treatment, fewer prednisone-treated patients (3 of 27) had developed generalized disease compared with 10 of 29 pyridostigmine-treated patients [<a href="#rid60">60</a>].</p><p>Neurologic worsening with initiation of high-dose <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> is less common in patients with OMG than with GMG. Nonetheless, starting with lower doses of 10 to 15 mg of prednisone daily and gradually increasing over three to four weeks is recommended, as some patients may have unrecognized GMG. Maximum daily doses of 0.5 to 1 mg/kg of prednisone are often needed for several weeks (occasionally months) in order to maintain benefit.</p><p>There is no single recommended dosing regimen. Because of the problematic side effects of chronic corticosteroid use, tapering to the lowest effective dose is essential after initial resolution and stabilization of symptoms. Low maintenance doses (5 to 10 mg every other day) are often effective in OMG, but response is highly variable. Alternate-day dosing is preferred. (See  <a class="medical medical_review" href="/d/html/5175.html" rel="external">"Chronic immunotherapy for myasthenia gravis", section on 'Glucocorticoids'</a>.)</p><p class="headingAnchor" id="H27"><span class="h3">Steroid-sparing agents and other immunosuppressive agents</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">Azathioprine</a>, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, and <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> are second-line immunosuppressants for patients who do not respond to or tolerate <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>. These agents can also be used with prednisone in order to wean prednisone. The side effects of these medications often limit their use for patients with OMG, but they may be necessary to control symptoms and may be preferred by patients if they do not experience major side effects [<a href="#rid63">63</a>]. While observational studies suggest that azathioprine reduces the risk of progression to GMG, further studies are required to confirm this finding [<a href="#rid55">55,62,64</a>]. Serious risks, such as lymphoma with azathioprine and renal toxicity with cyclosporine, must be weighed against symptom severity in individual patients. The role of <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a> for the treatment of MG is evolving, but response to and appropriateness for OMG is not known [<a href="#rid63">63</a>]. (See  <a class="medical medical_review" href="/d/html/5175.html" rel="external">"Chronic immunotherapy for myasthenia gravis", section on 'Glucocorticoid-sparing therapy'</a>.) </p><p class="headingAnchor" id="H28"><span class="h2">Thymectomy</span><span class="headingEndMark"> — </span>Thymectomy is required for patients who have a thymoma and myasthenia. Thymectomy is also recommended for certain patients with nonthymomatous GMG. This is discussed separately. (See  <a class="medical medical_review" href="/d/html/5127.html" rel="external">"Role of thymectomy in patients with myasthenia gravis"</a>.)</p><p>For nonthymomatous OMG, practice varies. Because prospective studies have not been performed in patients with nonthymomatous OMG, data regarding the benefit of thymectomy in these patients are limited. Several case series have demonstrated a similar response to thymectomy in OMG as with GMG [<a href="#rid65">65-68</a>]. Remission rates of 57 to 71 percent over more than five years have been reported after thymectomy in OMG patients [<a href="#rid68">68,69</a>]. In addition, no patients in two series of 96 total patients [<a href="#rid65">65,69</a>], and only 1 in a series of 61 patients [<a href="#rid67">67</a>], developed GMG after thymectomy. This contrasts with the expected 50 percent generalization rate over this timeframe. In a systematic review and meta-analysis of 26 studies, thymectomy was beneficial for nonthymomatous OMG, with complete stable remission of 51 percent, although substantial heterogeneity among studies limited certainty of this estimate [<a href="#rid70">70</a>].</p><p>Prospective, controlled trials are needed to determine if there is a reproducible beneficial effect of thymectomy in nonthymomatous OMG. In the meantime, while some centers do not advise thymectomy for patients with OMG in the absence of thymoma [<a href="#rid55">55,71</a>], others offer this as a therapeutic option, particularly if the less invasive extended-cervical procedure is performed [<a href="#rid72">72</a>]. Current guidelines note that thymectomy may be offered to patients with acetylcholine receptor antibody (AChR-Ab) positive nonthymomatous OMG who do not respond to acetylcholinesterase inhibitors or immunosuppressive agents or who have contraindications or cannot tolerate immunosuppressants [<a href="#rid63">63</a>].</p><p class="headingAnchor" id="H29"><span class="h2">Surgery for ptosis and diplopia</span><span class="headingEndMark"> — </span>Surgical correction can be performed on patients with stable ptosis. For patients who do not demonstrate stability prior to surgery, recurrence of ptosis is common due to the nature of myasthenia. The optimal duration of stability prior to surgery is unknown, although there are some indications that three to four years of stability prior to ptosis repair is appropriate [<a href="#rid73">73</a>]. (See  <a class="medical medical_review" href="/d/html/5243.html" rel="external">"Overview of ptosis"</a>.)</p><p>Extraocular muscle (strabismus) surgery can be performed on patients with stable symptomatic ophthalmoparesis that persists despite medication. Similar to the situation for ptosis, recurrence of diplopia is common for patients who do not demonstrate stability prior to surgery. The optimal duration of stability prior to surgery is unknown; shorter durations of stability (five to six months) prior to strabismus surgery are advocated compared with those recommended for ptosis surgery, but follow-up data on these patients are limited [<a href="#rid74">74</a>]. Based on natural history data, which indicate that myasthenia has a more stable course three years after onset [<a href="#rid2">2,75</a>], a conservative approach is to consider strabismus surgery three years after onset of OMG if deficits have been stable for at least one year and if the patient desires surgery and has either failed to respond to medical therapy or has contraindications for continued medical therapy.</p><p class="headingAnchor" id="H30"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – The diagnosis of ocular myasthenia gravis (OMG) is suggested by the triad of ophthalmoparesis, ptosis, and orbicularis oculi weakness; however, isolated ptosis and ophthalmoparesis are also common presentations. Demonstrating fatigue in the ocular muscles is a helpful but not infallible diagnostic sign for OMG. Pupillary function is spared. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – Clinicians should consider thyroid disease, muscle disease, and other brainstem and cranial nerve lesions in the differential diagnosis of OMG. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> – The diagnosis of OMG should be suspected in a patient with ophthalmoparesis, ptosis, and/or orbicularis oculi weakness, especially with a positive result on the ice test or evidence of fatiguability.</p><p></p><p class="bulletIndent1">A positive acetylcholine receptor antibody (AChR-Ab) titer confirms the diagnosis. If this is negative, then an electrophysiologic test should be performed.</p><p></p><p class="bulletIndent1">If the diagnosis remains unclear, then brain magnetic resonance imaging (MRI) and lumbar puncture (LP) should be performed to rule out other diagnoses. (See <a class="local">'Evaluation and diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional testing</strong> – Patients with suspected OMG should have thyroid function tests and a chest computed tomography (CT) to exclude thymoma. (See <a class="local">'Additional testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Progression to generalized MG (GMG)</strong> – Two-thirds of patients with OMG will develop signs and symptoms of extremity weakness and other bulbar muscle weakness, while one-third will have pure OMG. Most of those who will develop GMG do so within the first year, and virtually all will do so within three years. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medical treatment</strong> – We suggest anticholinesterase agents as a first treatment in OMG (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Most patients have some benefit from anticholinesterase agents, although many will not fully respond. (See <a class="local">'Anticholinesterase agents'</a> above.)</p><p></p><p class="bulletIndent1">For patients who continue to have disabling symptoms despite treatment with an anticholinesterase agent, we suggest immunosuppressive therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">Prednisone</a> is most commonly used. In deciding to use prednisone, clinicians and patients must balance the severity of symptoms and the efficacy of nonpharmacologic measures with the long-term side effects and the difficulty in weaning. (See <a class="local">'Immunosuppressive agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of thymectomy</strong> – Thymectomy is recommended for individuals with thymoma. (See  <a class="medical medical_review" href="/d/html/4619.html" rel="external">"Clinical presentation and management of thymoma and thymic carcinoma", section on 'Management of localized disease'</a>.)</p><p></p><p class="bulletIndent1">For most patients with nonthymomatous OMG, we suggest<strong> not </strong>performing thymectomy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). However, surgery may be considered in select patients with AChR-Ab and disabling, medically refractory disease or significant contraindications to medical treatment. This decision must consider the risks of progression to GMG and the risk of surgery. Less invasive (ie, thorascopic) surgeries at experienced medical centers can decrease the risk associated with thymectomy. (See <a class="local">'Treatment'</a> above and  <a class="medical medical_review" href="/d/html/5127.html" rel="external">"Role of thymectomy in patients with myasthenia gravis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Persistent diplopia and ptosis </strong>– Patients with stable diplopia or ptosis despite maximal medical therapy may benefit from surgical interventions. A period of stability of several months to a few years is suggested prior to surgical intervention. (See <a class="local">'Surgery for ptosis and diplopia'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Simpson JF, Westerberg MR, Magee KR. Myasthenia gravis. An analysis of 295 cases. Acta Neurol Scand 1966; 42:Suppl 23:1.</a></li><li><a class="nounderline abstract_t">Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci 1987; 505:472.</a></li><li><a class="nounderline abstract_t">Bever CT Jr, Aquino AV, Penn AS, et al. Prognosis of ocular myasthenia. Ann Neurol 1983; 14:516.</a></li><li><a class="nounderline abstract_t">Al-Haidar M, Benatar M, Kaminski HJ. Ocular Myasthenia. Neurol Clin 2018; 36:241.</a></li><li><a class="nounderline abstract_t">Kaminski HJ, Maas E, Spiegel P, Ruff RL. Why are eye muscles frequently involved in myasthenia gravis? Neurology 1990; 40:1663.</a></li><li><a class="nounderline abstract_t">Kaminski HJ, Li Z, Richmonds C, et al. Susceptibility of ocular tissues to autoimmune diseases. Ann N Y Acad Sci 2003; 998:362.</a></li><li><a class="nounderline abstract_t">Sommer N, Melms A, Weller M, Dichgans J. Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects. Doc Ophthalmol 1993; 84:309.</a></li><li><a class="nounderline abstract_t">COGAN DG. MYASTHENIA GRAVIS: A REVIEW OF THE DISEASE AND A DESCRIPTION OF LID TWITCH AS A CHARACTERISTIC SIGN. Arch Ophthalmol 1965; 74:217.</a></li><li><a class="nounderline abstract_t">Sethi KD, Rivner MH, Swift TR. Ice pack test for myasthenia gravis. Neurology 1987; 37:1383.</a></li><li><a class="nounderline abstract_t">Golnik KC, Pena R, Lee AG, Eggenberger ER. An ice test for the diagnosis of myasthenia gravis. Ophthalmology 1999; 106:1282.</a></li><li><a class="nounderline abstract_t">Chatzistefanou KI, Kouris T, Iliakis E, et al. The ice pack test in the differential diagnosis of myasthenic diplopia. Ophthalmology 2009; 116:2236.</a></li><li><a class="nounderline abstract_t">Osher RH, Glaser JS. Myasthenic sustained gaze fatigue. Am J Ophthalmol 1980; 89:443.</a></li><li class="breakAll">The Neuro-ophthalmic Examination. In: Neuro-Ophthalmology: Diagnosis and Management, 3rd ed, Liu G, Volpe N, Galetta S (Eds), Elsevier, Philadelphia 2018. p.29.</li><li><a class="nounderline abstract_t">Averbuch-Heller L, Poonyathalang A, von Maydell RD, Remler BF. Hering's law for eyelids: still valid. Neurology 1995; 45:1781.</a></li><li><a class="nounderline abstract_t">Ohkawa S, Yamasaki H, Ohsumi Y, et al. Eyebrow lifting test: a novel bedside test for narrowing of the palpebral fissure associated with peripheral facial nerve palsy. J Neurol Neurosurg Psychiatry 1997; 63:256.</a></li><li><a class="nounderline abstract_t">BAPTISTA AG, SILVA E SOUZA H. Pupillary abnormalities in myasthenia gravis. Report of a case. Neurology 1961; 11:210.</a></li><li><a class="nounderline abstract_t">Cooper J, Pollak GJ, Ciuffreda KJ, et al. Accommodative and vergence findings in ocular myasthenia: a case analysis. J Neuroophthalmol 2000; 20:5.</a></li><li class="breakAll">US Food and Drug Administration. FDA Drug Shortages. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Edrophonium+Chloride+%28ENLON%29+Injection%2C+USP&amp;st=d&amp;tab=tabs-2 (Accessed on August 16, 2018).</li><li><a class="nounderline abstract_t">Daroff RB. The office Tensilon test for ocular myasthenia gravis. Arch Neurol 1986; 43:843.</a></li><li><a class="nounderline abstract_t">Meriggioli MN, Sanders DB. Myasthenia gravis: diagnosis. Semin Neurol 2004; 24:31.</a></li><li><a class="nounderline abstract_t">Elrod RD, Weinberg DA. Ocular myasthenia gravis. Ophthalmol Clin North Am 2004; 17:275.</a></li><li class="breakAll">GeneReviews, Adam MP, Ardinger HH, Pagon RA, et al (Eds), University of Washington, Seattle 2018.</li><li><a class="nounderline abstract_t">Moorthy G, Behrens MM, Drachman DB, et al. Ocular pseudomyasthenia or ocular myasthenia 'plus': a warning to clinicians. Neurology 1989; 39:1150.</a></li><li><a class="nounderline abstract_t">Shams PN, Waldman A, Plant GT. B Cell lymphoma of the brain stem masquerading as myasthenia. J Neurol Neurosurg Psychiatry 2002; 72:271.</a></li><li><a class="nounderline abstract_t">Tummala RP, Harrison A, Madison MT, Nussbaum ES. Pseudomyasthenia resulting from a posterior carotid artery wall aneurysm: a novel presentation: case report. Neurosurgery 2001; 49:1466.</a></li><li><a class="nounderline abstract_t">Keane JR. Multiple cranial nerve palsies: analysis of 979 cases. Arch Neurol 2005; 62:1714.</a></li><li><a class="nounderline abstract_t">Lindstrom JM, Seybold ME, Lennon VA, et al. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976; 26:1054.</a></li><li><a class="nounderline abstract_t">Ahlskog JE, Petersen RC, Waring SC, et al. Guamanian neurodegenerative disease: are diabetes mellitus and altered humoral immunity clues to pathogenesis? Neurology 1997; 48:1356.</a></li><li><a class="nounderline abstract_t">Sanders DB, Andrews PI, Howard JF, Massey JM. Seronegative myasthenia gravis. Neurology 1997; 48:40S.</a></li><li><a class="nounderline abstract_t">Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 1985; 48:1246.</a></li><li><a class="nounderline abstract_t">Evoli A, Tonali P, Bartoccioni E, Lo Monaco M. Ocular myasthenia: diagnostic and therapeutic problems. Acta Neurol Scand 1988; 77:31.</a></li><li><a class="nounderline abstract_t">Soliven BC, Lange DJ, Penn AS, et al. Seronegative myasthenia gravis. Neurology 1988; 38:514.</a></li><li><a class="nounderline abstract_t">Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001; 7:365.</a></li><li><a class="nounderline abstract_t">McConville J, Farrugia ME, Beeson D, et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004; 55:580.</a></li><li><a class="nounderline abstract_t">Ohta K, Shigemoto K, Kubo S, et al. MuSK antibodies in AChR Ab-seropositive MG vs AChR Ab-seronegative MG. Neurology 2004; 62:2132.</a></li><li><a class="nounderline abstract_t">Caress JB, Hunt CH, Batish SD. Anti-MuSK myasthenia gravis presenting with purely ocular findings. Arch Neurol 2005; 62:1002.</a></li><li><a class="nounderline abstract_t">Hanisch F, Eger K, Zierz S. MuSK-antibody positive pure ocular myasthenia gravis. J Neurol 2006; 253:659.</a></li><li><a class="nounderline abstract_t">Bennett DL, Mills KR, Riordan-Eva P, et al. Anti-MuSK antibodies in a case of ocular myasthenia gravis. J Neurol Neurosurg Psychiatry 2006; 77:564.</a></li><li><a class="nounderline abstract_t">Zisimopoulou P, Evangelakou P, Tzartos J, et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun 2014; 52:139.</a></li><li><a class="nounderline abstract_t">Tsivgoulis G, Dervenoulas G, Kokotis P, et al. Double seronegative myasthenia gravis with low density lipoprotein-4 (LRP4) antibodies presenting with isolated ocular symptoms. J Neurol Sci 2014; 346:328.</a></li><li><a class="nounderline abstract_t">AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine. Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: summary statement. Muscle Nerve 2001; 24:1236.</a></li><li><a class="nounderline abstract_t">Younger DS, Worrall BB, Penn AS. Myasthenia gravis: historical perspective and overview. Neurology 1997; 48:S1.</a></li><li><a class="nounderline abstract_t">Costa J, Evangelista T, Conceição I, de Carvalho M. Repetitive nerve stimulation in myasthenia gravis--relative sensitivity of different muscles. Clin Neurophysiol 2004; 115:2776.</a></li><li><a class="nounderline abstract_t">Oh SJ, Kim DE, Kuruoglu R, et al. Diagnostic sensitivity of the laboratory tests in myasthenia gravis. Muscle Nerve 1992; 15:720.</a></li><li><a class="nounderline abstract_t">Sanders DB, Howard JF Jr. AAEE minimonograph #25: Single-fiber electromyography in myasthenia gravis. Muscle Nerve 1986; 9:809.</a></li><li><a class="nounderline abstract_t">AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine. Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome. Muscle Nerve 2001; 24:1239.</a></li><li><a class="nounderline abstract_t">Valls-Canals J, Povedano M, Montero J, Pradas J. Stimulated single-fiber EMG of the frontalis and orbicularis oculi muscles in ocular myasthenia gravis. Muscle Nerve 2003; 28:501.</a></li><li><a class="nounderline abstract_t">Mercelis R, Merckaert V. Diagnostic utility of stimulated single-fiber electromyography of the orbicularis oculi muscle in patients with suspected ocular myasthenia. Muscle Nerve 2011; 43:168.</a></li><li><a class="nounderline abstract_t">Krendel DA, Sanders DB, Massey JM. Single fiber electromyography in chronic progressive external ophthalmoplegia. Muscle Nerve 1987; 10:299.</a></li><li><a class="nounderline abstract_t">Milone M, Monaco ML, Evoli A, et al. Ocular myasthenia: diagnostic value of single fibre EMG in the orbicularis oculi muscle. J Neurol Neurosurg Psychiatry 1993; 56:720.</a></li><li><a class="nounderline abstract_t">Weinberg DH, Rizzo JF 3rd, Hayes MT, et al. Ocular myasthenia gravis: predictive value of single-fiber electromyography. Muscle Nerve 1999; 22:1222.</a></li><li><a class="nounderline abstract_t">Benatar M, Kaminski HJ, Quality Standards Subcommittee of the American Academy of Neurology. Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2007; 68:2144.</a></li><li><a class="nounderline abstract_t">Kupersmith MJ, Ying G. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment. Br J Ophthalmol 2005; 89:1330.</a></li><li><a class="nounderline abstract_t">Kupersmith MJ, Moster M, Bhuiyan S, et al. Beneficial effects of corticosteroids on ocular myasthenia gravis. Arch Neurol 1996; 53:802.</a></li><li><a class="nounderline abstract_t">Sommer N, Sigg B, Melms A, et al. Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry 1997; 62:156.</a></li><li><a class="nounderline abstract_t">Allen JA, Scala S, Jones HR. Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis. Muscle Nerve 2010; 41:379.</a></li><li><a class="nounderline abstract_t">Agius MA. Treatment of ocular myasthenia with corticosteroids: yes. Arch Neurol 2000; 57:750.</a></li><li><a class="nounderline abstract_t">Kaminski HJ, Daroff RB. Treatment of ocular myasthenia: steroids only when compelled. Arch Neurol 2000; 57:752.</a></li><li><a class="nounderline abstract_t">Bhanushali MJ, Wuu J, Benatar M. Treatment of ocular symptoms in myasthenia gravis. Neurology 2008; 71:1335.</a></li><li><a class="nounderline abstract_t">Monsul NT, Patwa HS, Knorr AM, et al. The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci 2004; 217:131.</a></li><li><a class="nounderline abstract_t">Kupersmith MJ. Does early treatment of ocular myasthenia gravis with prednisone reduce progression to generalized disease? J Neurol Sci 2004; 217:123.</a></li><li><a class="nounderline abstract_t">Benatar M, Kaminski H. Medical and surgical treatment for ocular myasthenia. Cochrane Database Syst Rev 2006; :CD005081.</a></li><li><a class="nounderline abstract_t">Narayanaswami P, Sanders DB, Wolfe G, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 2021; 96:114.</a></li><li><a class="nounderline abstract_t">Mee J, Paine M, Byrne E, et al. Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuroophthalmol 2003; 23:251.</a></li><li><a class="nounderline abstract_t">Schumm F, Wiethölter H, Fateh-Moghadam A, Dichgans J. Thymectomy in myasthenia with pure ocular symptoms. J Neurol Neurosurg Psychiatry 1985; 48:332.</a></li><li><a class="nounderline abstract_t">Lanska DJ. Indications for thymectomy in myasthenia gravis. Neurology 1990; 40:1828.</a></li><li><a class="nounderline abstract_t">Roberts PF, Venuta F, Rendina E, et al. Thymectomy in the treatment of ocular myasthenia gravis. J Thorac Cardiovasc Surg 2001; 122:562.</a></li><li><a class="nounderline abstract_t">Huang CS, Hsu HS, Huang BS, et al. Factors influencing the outcome of transsternal thymectomy for myasthenia gravis. Acta Neurol Scand 2005; 112:108.</a></li><li><a class="nounderline abstract_t">Shrager JB, Deeb ME, Mick R, et al. Transcervical thymectomy for myasthenia gravis achieves results comparable to thymectomy by sternotomy. Ann Thorac Surg 2002; 74:320.</a></li><li><a class="nounderline abstract_t">Zhu K, Li J, Huang X, et al. Thymectomy is a beneficial therapy for patients with non-thymomatous ocular myasthenia gravis: a systematic review and meta-analysis. Neurol Sci 2017; 38:1753.</a></li><li><a class="nounderline abstract_t">Gilbert ME, De Sousa EA, Savino PJ. Ocular Myasthenia Gravis treatment: the case against prednisone therapy and thymectomy. Arch Neurol 2007; 64:1790.</a></li><li><a class="nounderline abstract_t">Chavis PS, Stickler DE, Walker A. Immunosuppressive or surgical treatment for ocular Myasthenia Gravis. Arch Neurol 2007; 64:1792.</a></li><li><a class="nounderline abstract_t">Castronuovo S, Krohel GB, Kristan RW. Blepharoptosis in myasthenia gravis. Ann Ophthalmol 1983; 15:751.</a></li><li><a class="nounderline abstract_t">Davidson JL, Rosenbaum AL, McCall LC. Strabismus surgery in patients with myasthenia. J Pediatr Ophthalmol Strabismus 1993; 30:292.</a></li><li><a class="nounderline abstract_t">Oosterhuis HJ. The natural course of myasthenia gravis: a long term follow up study. J Neurol Neurosurg Psychiatry 1989; 52:1121.</a></li></ol></div><div id="topicVersionRevision">Topic 5242 Version 12.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5957970" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Myasthenia gravis. An analysis of 295 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3318620" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The course of myasthenia gravis and therapies affecting outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6651238" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prognosis of ocular myasthenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29655447" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Ocular Myasthenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1700335" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Why are eye muscles frequently involved in myasthenia gravis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14592898" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Susceptibility of ocular tissues to autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8156854" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14318498" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : MYASTHENIA GRAVIS: A REVIEW OF THE DISEASE AND A DESCRIPTION OF LID TWITCH AS A CHARACTERISTIC SIGN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3614664" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Ice pack test for myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10406606" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : An ice test for the diagnosis of myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19744729" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The ice pack test in the differential diagnosis of myasthenic diplopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7369304" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Myasthenic sustained gaze fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7369304" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Myasthenic sustained gaze fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7675249" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Hering's law for eyelids: still valid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9285471" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Eyebrow lifting test: a novel bedside test for narrowing of the palpebral fissure associated with peripheral facial nerve palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13686639" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pupillary abnormalities in myasthenia gravis. Report of a case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10770497" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Accommodative and vergence findings in ocular myasthenia: a case analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10770497" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Accommodative and vergence findings in ocular myasthenia: a case analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3729767" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The office Tensilon test for ocular myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15229790" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Myasthenia gravis: diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15337189" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Ocular myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15337189" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Ocular myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2771063" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Ocular pseudomyasthenia or ocular myasthenia 'plus': a warning to clinicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11796784" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : B Cell lymphoma of the brain stem masquerading as myasthenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11846949" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pseudomyasthenia resulting from a posterior carotid artery wall aneurysm: a novel presentation: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16286545" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Multiple cranial nerve palsies: analysis of 979 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/988512" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9153473" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Guamanian neurodegenerative disease: are diabetes mellitus and altered humoral immunity clues to pathogenesis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Seronegative myasthenia gravis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4087000" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3354309" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Ocular myasthenia: diagnostic and therapeutic problems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3352902" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Seronegative myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11231638" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15048899" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Detection and characterization of MuSK antibodies in seronegative myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15184636" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : MuSK antibodies in AChR Ab-seropositive MG vs AChR Ab-seronegative MG.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15956173" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Anti-MuSK myasthenia gravis presenting with purely ocular findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16311895" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : MuSK-antibody positive pure ocular myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16543546" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Anti-MuSK antibodies in a case of ocular myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24373505" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25248951" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Double seronegative myasthenia gravis with low density lipoprotein-4 (LRP4) antibodies presenting with isolated ocular symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11494280" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: summary statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Myasthenia gravis: historical perspective and overview</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15546785" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Repetitive nerve stimulation in myasthenia gravis--relative sensitivity of different muscles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1324429" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Diagnostic sensitivity of the laboratory tests in myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3785290" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : AAEE minimonograph #25: Single-fiber electromyography in myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11494281" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14506723" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Stimulated single-fiber EMG of the frontalis and orbicularis oculi muscles in ocular myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21254079" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Diagnostic utility of stimulated single-fiber electromyography of the orbicularis oculi muscle in patients with suspected ocular myasthenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3587264" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Single fiber electromyography in chronic progressive external ophthalmoplegia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8509796" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Ocular myasthenia: diagnostic value of single fibre EMG in the orbicularis oculi muscle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10454717" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Ocular myasthenia gravis: predictive value of single-fiber electromyography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17460154" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16170126" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8759987" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Beneficial effects of corticosteroids on ocular myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9048716" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Ocular myasthenia gravis: response to long-term immunosuppressive treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19918767" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10815145" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Treatment of ocular myasthenia with corticosteroids: yes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10815146" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Treatment of ocular myasthenia: steroids only when compelled.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18936425" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Treatment of ocular symptoms in myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14706214" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The effect of prednisone on the progression from ocular to generalized myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14706212" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Does early treatment of ocular myasthenia gravis with prednisone reduce progression to generalized disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16625623" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Medical and surgical treatment for ocular myasthenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33144515" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14663303" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3998738" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Thymectomy in myasthenia with pure ocular symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2247228" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Indications for thymectomy in myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11547310" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Thymectomy in the treatment of ocular myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16008537" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Factors influencing the outcome of transsternal thymectomy for myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12173807" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Transcervical thymectomy for myasthenia gravis achieves results comparable to thymectomy by sternotomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28707128" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Thymectomy is a beneficial therapy for patients with non-thymomatous ocular myasthenia gravis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18071047" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Ocular Myasthenia Gravis treatment: the case against prednisone therapy and thymectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18071048" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Immunosuppressive or surgical treatment for ocular Myasthenia Gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6660720" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Blepharoptosis in myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8254443" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Strabismus surgery in patients with myasthenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2795037" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The natural course of myasthenia gravis: a long term follow up study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
